MXCT

Over the past six months, MaxCyte, Inc. (MXCT) stock price has experienced fluctuations, declining by 20.00% over the past year to $1.16 as of September 11, 2026, from $1.45 on September 15, 2025. The stock's price decreased by 26.23% over the last 12 months, with a year-to-date return of -22.90% as of September 18, 2026. During the past year, MXCT stock traded between a low of $0.64 and a high of $1.87. Key events impacting the stock include MaxCyte reiterating its full-year 2026 revenue outlook of $30 million to $32 million in August 2026. The company reported its fourth-quarter and full-year 2025 financial results on March 24, 2026, with total revenue for 2025 at $33.0 million, a 15% decrease from 2024. MaxCyte also reported its first-quarter 2026 financial results on May 12, 2026, with total revenue of $9.7 million, a 7% decrease over the first quarter of 2025. An operational restructuring aimed at reducing costs and accelerating the path to profitability was announced in September 2025.